Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$36.90 USD
-0.02 (-0.05%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $36.87 -0.03 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BHVN 36.90 -0.02(-0.05%)
Will BHVN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BHVN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BHVN
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
BHVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -32.76% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Other News for BHVN
RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
Biohaven initiated with bullish view at Bernstein, here's why
Biohaven Breaks Above 200-Day Moving Average - Bullish for BHVN
Optimistic Outlook: Buy Rating on Biohaven Ltd. for Strategic Approach and Promising R&D Pipeline
BofA starts Biohaven at buy, cites "fast-follower" approach